STOCK TITAN

Geron (GERN) Stock Price, News & Analysis

GERN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
44 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+21.6% close of August 5, 2026
1-year change
-10.7% closing prices, November 18, 2025 to November 18, 2026
1-month change
-15.3% closing prices, October 16, 2026 to November 18, 2026

Company Description

Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company in the pharmaceutical preparation manufacturing industry, focused on changing the course of blood cancers and related myeloid hematologic malignancies. According to the company’s public disclosures, Geron’s work centers on telomerase inhibition, a targeted approach that aims to address diseases driven by malignant stem and progenitor cells in the bone marrow.

Geron’s primary therapeutic asset is RYTELO (imetelstat), described as a first-in-class oligonucleotide telomerase inhibitor. RYTELO is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia. In the U.S., it is indicated for adult patients with LR-MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. In the EU, it is approved as monotherapy for adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is indicated to be administered as an intravenous infusion over two hours every four weeks. Geron states that RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission. The company also notes that RYTELO is developed and exclusively owned by Geron.

Geron explains that telomeres are protective caps at the end of chromosomes that naturally shorten with each cell division. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds telomeres and can allow uncontrolled cell division. By inhibiting telomerase enzymatic activity, imetelstat is intended to target malignant stem and progenitor cells, with the aim of potentially reducing their proliferation and inducing cell death. This biological rationale underpins Geron’s broader development strategy in myeloid malignancies.

Business focus and revenue sources

Geron describes itself as a company aiming to build a sustainable hematology-focused business. Earlier descriptions of the company characterize it as a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments, with revenue historically generated from collaboration agreements, milestones, royalties and licensing arrangements, and operating as a single segment dedicated to the development of therapeutic products for oncology. More recent disclosures highlight net product revenue from RYTELO as an additional source of revenue, alongside license fees and royalties.

The company has discussed expectations for RYTELO net product revenue and total operating expenses in its financial guidance, and has referenced a strategic restructuring plan intended to streamline operations and support its commercial and clinical development priorities. Geron has indicated that its restructuring is designed to support the RYTELO U.S. commercial strategy, investment in clinical development and what it describes as long-term value creation for patients and shareholders.

Clinical development programs

Beyond its approved indication in LR-MDS, Geron is conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), known as the IMpactMF trial. Company disclosures describe IMpactMF as an open-label, randomized, controlled Phase 3 trial with registrational intent, enrolling approximately 320 patients with intermediate-2 or high-risk myelofibrosis who are relapsed after or refractory to prior treatment with a JAK inhibitor. Patients are randomized to receive either imetelstat or best available therapy, with overall survival as the primary endpoint and key secondary endpoints including symptom response, spleen response, progression-free survival, complete and partial remission, clinical improvement, duration of response, safety, pharmacokinetics and patient-reported outcomes.

Geron is also involved in additional studies in myeloid hematologic malignancies. These include analyses and trials in myelofibrosis, advanced myelodysplastic neoplasms and acute myeloid leukemia, as reflected in data presented at the American Society of Hematology (ASH) meetings and in investigator-sponsored studies. The company has highlighted exploratory biomarker work, including analyses of inflammatory cytokines such as IL-8 and TNF-alpha in myelofibrosis, and has reported on combination approaches such as the IMproveMF Phase 1b trial evaluating imetelstat plus ruxolitinib in intermediate-2 or high-risk myelofibrosis.

Scientific evidence and data presentations

Geron regularly reports clinical and translational data related to RYTELO/imetelstat. At ASH 2025, the company described pooled analyses from the Phase 3 IMerge trial in LR-MDS, examining the relationship between treatment-emergent cytopenias and clinical outcomes such as hemoglobin increases and red blood cell transfusion independence. These analyses suggested that certain early reductions in neutrophils and platelets may be associated with greater hemoglobin increases and higher rates of transfusion independence in patients treated with imetelstat.

Long-term follow-up data from IMerge have also been reported, including trends in overall survival, progression-free survival and time to progression to acute myeloid leukemia for imetelstat-treated patients compared with placebo. Geron has characterized these results as supporting a favorable trend, while noting that the trial was not powered to detect statistical significance for overall survival.

In myelofibrosis, Geron has presented analyses from the Phase 2 IMbark trial, including correlations between changes in cytokine levels and clinical endpoints such as symptom improvement, spleen volume reduction and survival trends. The company has also described interim results from the IMpress investigator-sponsored study in advanced myelodysplastic neoplasms or AML failing hypomethylating agent-based therapy, noting manageable safety at the studied dose and limited single-agent activity in that high-risk population, with implications for potential combination strategies.

Corporate strategy and restructuring

Geron has communicated a set of strategic priorities that include driving RYTELO commercial growth in the U.S., pursuing paths to make RYTELO available in LR-MDS markets outside the U.S., and advancing the Phase 3 IMpactMF trial. To support these goals, the company announced a strategic restructuring plan approved by its Board of Directors, which includes a reduction in workforce of approximately one-third of its then-current employee base. An associated Form 8-K filing estimates restructuring and related charges primarily tied to severance and employee-related costs, with the plan expected to be substantially complete in the first quarter of 2026.

Geron describes this restructuring as intended to streamline the organizational structure, improve financial discipline, support the RYTELO commercial strategy and maintain investment in clinical development. The company has also reported executive leadership transitions and new appointments, including changes in its chief executive officer and commercial leadership, with the stated aim of aligning its leadership structure with its strategic priorities around hematology-oncology and the commercialization of RYTELO.

Regulatory and safety information

Public materials about RYTELO include important safety information consistent with its prescribing information. Reported warnings and precautions include risks of thrombocytopenia, neutropenia, infusion-related reactions and embryo-fetal toxicity. The company notes that serious adverse reactions, including sepsis and other events, have occurred in patients treated with RYTELO, and that monitoring of blood counts, infection risk and infusion-related reactions is recommended, along with supportive measures such as transfusions, growth factors and anti-infective therapies as appropriate. Geron also advises that RYTELO can cause embryo-fetal harm based on animal findings and that females of reproductive potential should use effective contraception during treatment and for a specified period after the last dose.

Geron’s disclosures emphasize that detailed prescribing information, including full safety data and medication guides, is available in the official RYTELO prescribing information documents referenced in its communications.

Position within the biopharmaceutical sector

Within the broader manufacturing sector, Geron fits into the pharmaceutical preparation manufacturing category, with a focus on oncology and hematology. Its specialization in telomerase inhibition and concentration on LR-MDS and myelofibrosis distinguish its scientific and clinical focus among biopharmaceutical companies. The company’s activities span drug discovery, clinical development, regulatory engagement, commercialization of an approved therapy, and ongoing post-approval and pipeline studies in myeloid hematologic malignancies.

Stock Performance

$0.9909
-0.91%
-0.0091
Last updated: at
-10.7%
Performance 1 year
$638.4M

Geron (GERN) closed at $0.9909 on November 18, 2026. Over the past 12 months, the price has lost 10.7%.

See what a $1,000 investment in GERN would be worth today

Average down calculator for GERN

GERN Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Geron has 10 recent news articles, with the latest published on . Of the recent coverage, 5 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, clinical trial, earnings date, conferences. View all GERN news →

Insider Radar

Net Buyers
90-Day Summary
65,500
Shares Bought
0
Shares Sold
2
Transactions
Most Recent Transaction
Williams Timothy (EVP and Chief Legal Officer) bought 12,000 shares @ $0.9400 on November 16, 2026

Insider buying activity at Geron over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Geron reported operating income of -$68.6M in FY2025, and net income was -$83.5M. Diluted earnings per share stood at -$0.13. The company generated -$111.0M in operating cash flow. The current ratio was 4.66, measuring current assets divided by current liabilities.

-$83.5M
Net Income (FY2025)
-$111.0M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
12
December 12, 2026 - December 16, 2026 Marketing

ASH Annual Meeting

American Society of Hematology Annual Meeting in New Orleans; Geron presenting six posters Dec 12–16, 2026.
DEC
12
December 12, 2026 - December 13, 2026 Marketing

Geron Poster Sessions

Geron poster sessions at ASH in New Orleans scheduled on Dec 12 and Dec 13, 2026 with six presentations on imetelstat.
DEC
31
December 31, 2026 Product

Germany availability

RYTELO availability in Germany as part of staged European launch; expected by 2026 year-end, affecting local patient access.
YEAR
2027
2027 Product

France availability

RYTELO expected to become available in France in 2027 as part of the staged European launch; timing subject to market access.
MAR
17
March 17, 2027 - September 17, 2030 Corporate

Option vesting period

821,250 inducement stock options vesting begins 6-month anniversary 2027-03-17 and continues monthly through 2030-09-17.
MAY
17
May 17, 2027 Corporate

Initial option vesting

12.5% of 150,000 options vests six months after Nov 17, 2026 effective date; $1.00 exercise price applies
H2
2028
H2 2028 Clinical

Final OS analysis

Final overall survival analysis for Phase 3 IMpactMF trial
APR
13
April 13, 2030 Corporate

Full option vesting

Remaining portions fully vest on Apr 13, 2030 under four-year schedule; 2.5M shares, $1.73 exercise price.
APR
17
April 17, 2030 Corporate

Final vesting completion

Remaining inducement options fully vest four years after the Apr 17, 2026 grant, totaling 855,000 options.
AUG
17
August 17, 2030 Corporate

Employee options vesting

Four-year vesting completes for 311,250 options granted Aug 17, 2026 under Geron’s 2018 Inducement Award Plan; may create dilution.
NOV
17
November 17, 2030 Corporate

Final option vesting

Remaining options vest in equal installments over the 42 months following initial vesting; $1.00 exercise price
MAR
17
March 17, 2036 Corporate

Option expiration

10-year term ends; unexercised options expire; exercise price $1.62; 956,250 shares
APR
13
April 13, 2036 Corporate

Option expiration

10-year term ends Apr 13, 2036 for 2,500,000-share option granted Apr 13, 2026 to EVP Williams; $1.73 exercise.
JUL
13
July 13, 2036 Corporate

Rath Option Expiration

Option expiration for 1,700,000-share grant to CBO Chinmaya Rath, exercise price $1.42; expires 2036-07-13 (10-year term).
AUG
17
August 17, 2036 Corporate

Option expiration date

Ten-year term ends for 311,250 options granted Aug 17, 2026; options expire if unexercised, affecting potential share count.

Geron has 15 upcoming scheduled events. The next event, "ASH Annual Meeting", is scheduled for December 12, 2026 (in 24 days). Investors can track these dates to stay informed about potential catalysts that may affect the GERN stock price.

Short Interest History

Last 12 Months

Short interest in Geron (GERN) currently stands at 67.0 million shares, down 10.3% from the previous reporting period, representing 10.5% of the float. Since November 2025, short interest has decreased by 13.5%.

Days to Cover History

Last 12 Months

Days to cover for Geron (GERN) currently stands at 3.9 days, down 60.3% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 64.4%. Across the settlements charted above, it has ranged from 2.9 to 11.6 days.

GERN Company Profile & Sector Positioning

Geron (GERN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing GERN often look at related companies in the same sector, including Cullinan Therapeutics, Inc. (CGEM), Bicara Therapeutics Inc. (BCAX), Aclaris Therapeutics, Inc. (ACRS), Climb Bio, Inc. (CLYM), and Adlai Nortye Group Ltd. (ANL). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GERN's relative position within its industry.

Frequently Asked Questions

The current stock price of Geron (GERN) is $0.9909 as of November 18, 2026.

The market cap of Geron (GERN) is approximately $638.4M. Learn more about what market capitalization means .

The FY2025 net income of Geron (GERN) is -$83.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Geron (GERN) is -$0.13 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Geron (GERN) is -$111.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Geron (GERN), current assets divided by current liabilities, was 4.66 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Geron (GERN) is -$68.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies. Its work centers on telomerase inhibition, and its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.

RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor developed and exclusively owned by Geron. It is approved in the U.S. and EU for specific adult patients with lower-risk myelodysplastic syndromes and transfusion-dependent anemia. RYTELO is administered as an intravenous infusion over two hours every four weeks and is described by Geron as the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Geron explains that imetelstat works by inhibiting telomerase enzymatic activity. In lower-risk myelodysplastic syndromes, abnormal bone marrow cells often express telomerase, which rebuilds telomeres and can allow uncontrolled cell division. By inhibiting telomerase, imetelstat is intended to target malignant stem and progenitor cells, with the aim of potentially reducing their proliferation and inducing cell death.

RYTELO is approved in the United States for adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. In the European Union, it is approved as monotherapy for adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

Geron is conducting the IMpactMF Phase 3 trial, an open-label, randomized, controlled study with registrational intent in patients with intermediate-2 or high-risk myelofibrosis who are relapsed after or refractory to prior JAK inhibitor treatment. The company also references additional studies in other myeloid hematologic malignancies, including trials and analyses in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia, as well as a Phase 1b combination trial called IMproveMF evaluating imetelstat plus ruxolitinib.

Earlier descriptions of Geron characterize it as a clinical-stage biopharmaceutical company that earns revenue through collaboration agreements, milestones, royalties and licensing arrangements, operating as a single segment focused on developing therapeutic products for oncology. More recent disclosures add that Geron generates net product revenue from RYTELO, along with license fees and royalties.

IMpactMF is Geron’s Phase 3 clinical trial evaluating imetelstat in patients with intermediate-2 or high-risk myelofibrosis who are relapsed after or refractory to prior JAK inhibitor treatment. Patients are randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival, and key secondary endpoints include symptom response, spleen response, progression-free survival, complete and partial remission, clinical improvement, duration of response, safety, pharmacokinetics and patient-reported outcomes.

Geron has announced a strategic restructuring plan approved by its Board of Directors, which includes a reduction in workforce of approximately one-third of its then-current employees. According to the company’s Form 8-K and press releases, the plan is intended to position the company for long-term value creation for patients and shareholders, improve financial discipline, support the RYTELO U.S. commercial strategy and maintain investment in clinical development. The company expects the reduction in workforce to be substantially complete in the first quarter of 2026.

Geron’s public materials on RYTELO describe warnings and precautions for thrombocytopenia, neutropenia, infusion-related reactions and embryo-fetal toxicity. Serious adverse reactions, including sepsis and other events, have been reported in patients treated with RYTELO. The company recommends monitoring blood counts, watching for infections and infusion-related reactions, and using supportive measures such as transfusions, growth factors and anti-infective therapies as appropriate, with further details provided in the full prescribing information.

Geron describes itself as aiming to change lives by changing the course of blood cancer, with a focus on hematology and myeloid malignancies. Its strategy centers on telomerase inhibition through its first-in-class product RYTELO and on advancing clinical programs such as IMpactMF in myelofibrosis, while building a commercial-stage hematology business around its approved indication in lower-risk myelodysplastic syndromes.